Cardiometabolic Disease Market Research Report—Global Forecast till 2032

Cardiometabolic Disease Market Research Report Information By Treatment (Angiotensin-converting Enzyme (ACE) Inhibitors, Diuretics, Glucophage, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

ID: MRFR/HC/10031-HCR | 128 Pages | Author: Rahul Gotadki | March 2024         

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT

6.1. Overview

6.2. Angiotensin-converting Enzyme (ace) Inhibitors

6.3. Diuretics

6.4. Glucophage

6.5. Others

7. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.2. Hospital Pharmacies

7.3. Retail Pharmacies

7.4. Online Pharmacies

7.5. Others

8. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY REGION

8.1. Overview

1.1. North America

1.1.1. US

1.1.2. Canada

1.2. Europe

1.2.1. Germany

1.2.2. France

1.2.3. UK

1.2.4. Italy

1.2.5. Spain

1.2.6. Rest of Europe

1.3. Asia-Pacific

1.3.1. China

1.3.2. India

1.3.3. Japan

1.3.4. South Korea

1.3.5. Australia

1.3.6. Rest of Asia-Pacific

1.4. Rest of the World

1.4.1. Middle East

1.4.2. Africa

1.4.3. Latin America

2. COMPETITIVE LANDSCAPE

2.1. Overview

2.2. Competitive Analysis

2.3. Market Share Analysis

2.4. Major Growth Strategy in the Global Cardiometabolic Disease Market,

2.5. Competitive Benchmarking

2.6. Leading Players in Terms of Number of Developments in the Global Cardiometabolic Disease Market,

2.7. Key developments and Growth Strategies

2.7.1. New Product Launch/Service Deployment

2.7.2. Merger & Acquisitions

2.7.3. Joint Ventures

2.8. Major Players Financial Matrix

2.8.1. Sales & Operating Income, 2022

2.8.2. Major Players R&D Expenditure. 2022

3. COMPANY PROFILES

3.1. Cardax, Inc.

3.1.1. Company Overview

3.1.2. Financial Overview

3.1.3. Products Offered

3.1.4. Key Developments

3.1.5. SWOT Analysis

3.1.6. Key Strategies

3.2. Novartis AG

3.2.1. Company Overview

3.2.2. Financial Overview

3.2.3. Products Offered

3.2.4. Key Developments

3.2.5. SWOT Analysis

3.2.6. Key Strategies

3.3. Novo Nordisk A/S

3.3.1. Company Overview

3.3.2. Financial Overview

3.3.3. Products Offered

3.3.4. Key Developments

3.3.5. SWOT Analysis

3.3.6. Key Strategies

3.4. Eli Lilly and Company

3.4.1. Company Overview

3.4.2. Financial Overview

3.4.3. Products Offered

3.4.4. Key Developments

3.4.5. SWOT Analysis

3.4.6. Key Strategies

3.5. Bayer AG

3.5.1. Company Overview

3.5.2. Financial Overview

3.5.3. Products Offered

3.5.4. Key Developments

3.5.5. SWOT Analysis

3.5.6. Key Strategies

3.6. Allergan

3.6.1. Company Overview

3.6.2. Financial Overview

3.6.3. Products Offered

3.6.4. Key Developments

3.6.5. SWOT Analysis

3.6.6. Key Strategies

3.7. Boehringer Ingelheim International GmbH

3.7.1. Company Overview

3.7.2. Financial Overview

3.7.3. Products Offered

3.7.4. Key Developments

3.7.5. SWOT Analysis

3.7.6. Key Strategies

3.8. ASTRAZENECA

3.8.1. Company Overview

3.8.2. Financial Overview

3.8.3. Products Offered

3.8.4. Key Developments

3.8.5. SWOT Analysis

3.8.6. Key Strategies

4. APPENDIX

4.1. References

4.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SYNOPSIS, 2018-2032

TABLE 2 GLOBAL CARDIOMETABOLIC DISEASE MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)

TABLE 3 GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 4 GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 5 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 7 US: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 8 US: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 9 CANADA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 10 CANADA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 1 EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 2 EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 3 GERMANY: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 4 GERMANY: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 5 FRANCE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 6 FRANCE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 7 ITALY: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 8 ITALY: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 9 SPAIN: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 10 SPAIN: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 11 UK: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 12 UK: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 13 REST OF EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 14 REST OF EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 15 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 16 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 17 JAPAN: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 18 JAPAN: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 19 CHINA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 20 CHINA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 21 INDIA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 22 INDIA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 23 AUSTRALIA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 24 AUSTRALIA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 25 SOUTH KOREA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 26 SOUTH KOREA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 27 REST OF ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 28 REST OF ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 29 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 30 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 31 MIDDLE EAST: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 32 MIDDLE EAST: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 33 AFRICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 34 AFRICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 35 LATIN AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)

TABLE 36 LATIN AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CARDIOMETABOLIC DISEASE MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CARDIOMETABOLIC DISEASE MARKET

FIGURE 4 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY TREATMENT, 2022

FIGURE 5 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022

FIGURE 6 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022

FIGURE 7 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 EUROPE: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 GLOBAL CARDIOMETABOLIC DISEASE MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 12 CARDAX, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 CARDAX, INC.: SWOT ANALYSIS

FIGURE 14 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 NOVARTIS AG: SWOT ANALYSIS

FIGURE 16 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 NOVO NORDISK A/S: SWOT ANALYSIS

FIGURE 18 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 ELI LILLY AND COMPANY: SWOT ANALYSIS

FIGURE 20 BAYER AG.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 BAYER AG.: SWOT ANALYSIS

FIGURE 22 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 ALLERGAN: SWOT ANALYSIS

FIGURE 24 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS

FIGURE 26 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 ASTRAZENECA: SWOT ANALYSIS

Cardiometabolic Disease Market Segmentation


Cardiometabolic Disease Treatment Outlook (USD Billion, 2018-2032)




  • Angiotensin-converting Enzyme (ace) Inhibitors




  • Diuretics




  • Glucophage




  • Others




Cardiometabolic Disease Distribution Channel Outlook (USD Billion, 2018-2032)




  • Hospital Pharmacies




  • Retail Pharmacies




  • Online Pharmacies




  • Others




Cardiometabolic Disease Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)




    • North America Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • North America Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • US Outlook (USD Billion, 2018-2032)




    • US Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • US Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • CANADA Outlook (USD Billion, 2018-2032)




    • CANADA Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • CANADA Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others








  • Europe Outlook (USD Billion, 2018-2032)




    • Europe Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Europe Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • Germany Outlook (USD Billion, 2018-2032)




    • Germany Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Germany Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • France Outlook (USD Billion, 2018-2032)




    • France Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • France Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • UK Outlook (USD Billion, 2018-2032)




    • UK Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • UK Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • ITALY Outlook (USD Billion, 2018-2032)




    • ITALY Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • ITALY Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • SPAIN Outlook (USD Billion, 2018-2032)




    • Spain Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Spain Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Rest Of Europe Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • REST OF EUROPE Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Asia-Pacific Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Asia-Pacific Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • China Outlook (USD Billion, 2018-2032)




    • China Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • China Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • Japan Outlook (USD Billion, 2018-2032)




    • Japan Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Japan Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • India Outlook (USD Billion, 2018-2032)




    • India Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • India Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • Australia Outlook (USD Billion, 2018-2032)




    • Australia Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Australia Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Rest of Asia-Pacific Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Rest of Asia-Pacific Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Rest of the World Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Rest of the World Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • Middle East Outlook (USD Billion, 2018-2032)




    • Middle East Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Middle East Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • Africa Outlook (USD Billion, 2018-2032)




    • Africa Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Africa Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others






    • Latin America Outlook (USD Billion, 2018-2032)




    • Latin America Cardiometabolic Disease by Treatment




      • Angiotensin-converting Enzyme (ace) Inhibitors




      • Diuretics




      • Glucophage




      • Others






    • Latin America Cardiometabolic Disease by Distribution Channel




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies




      • Others







Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid